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Abstract
Objectives To evaluate the performance of diffusion-
weighted MRI (DWI) in addition to T2-weighted (T2W)
MRI for nodal restaging after chemoradiation in rectal
cancer.
Methods Thirty patients underwent chemoradiation followed
by MRI (1.5 T) and surgery. Imaging consisted of T2W-MRI
and DWI (b0, 500, 1000). On T2W-MRI, nodes were scored
as benign/malignant by two independent readers (R1, R2).
Mean apparent diffusion coefficient (ADC) was measured for
each node. Diagnostic performance was compared for T2W-
MRI, ADC and T2W+ADC, using a per lesion histological
validation.
Results ADC was higher for the malignant nodes (1.43±
0.38 vs 1.19±0.27 *10
−3 mm
2/s, p<0.001). Area under
the ROC curve/sensitivity/specificity were 0.88/65%/93%
(R1) and 0.95/71%/91% (R2) using T2W-MRI; 0.66/53%/
82% using ADC (mean of two readers); and 0.91/56%/
98% (R1) and 0.96/56%/99% (R2) using T2W+ADC.
There was no significant difference between T2W-MRI
and T2W+ADC. Interobserver reproducibility was good
for T2W-MRI (κ0.73) and ADC (intraclass correlation
coefficient 0.77).
Conclusions After chemoradiation, ADC measurements
may have potential for nodal characterisation, but DWI
on its own is not reliable. Addition of DWI to T2W-
MRI does not improve accuracy and T2W-MRI is
already sufficiently accurate.
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Introduction
Nodal involvement constitutes one of the most significant risk
factors for local recurrence in rectal cancer [1]. For patients
with node-positive disease the standard treatment consists of a
long course of chemoradiation therapy (CRT), followed by
surgery. In up to 35% of patients, no residual tumour cells are
found at histological evaluation after surgery [2, 3]. These
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outcome, with respect to local control and survival [4, 5].
Therefore, it is now increasingly being suggested that
minimally invasive treatments, such as a local excision or a
wait-and-see policy be advocated as an alternative to standard
s u r g e r yw i t ht h ea i mo fr e d u c i n gt reatment-related morbidity
and mortality [6, 7]. When doing so it is, however, mandatory
to ensure that no metastatic nodes are left behind and that the
true node-negative (the ypN0) patients are accurately selected.
CT, endoluminal ultrasound and MRI are all known to be
insufficiently accurate with sensitivities and specificities in the
55–78% range, although some authors have reported more
encouraging results after CRT [8–11].
Diffusion-weighted MRI (DWI) could be a potentially
valuable oncological imaging technique. DWI uses differences
in water motion to discriminate between tissues of varying
cellularity. As lymph nodes have a high cellular density, they
generally show restricted diffusion and are easily detected on
DWI [12, 13]. Quantification of the apparent diffusion
coefficient (ADC) could be useful to discriminate between
benign and metastatic nodes, as the cellular density—and
therefore the diffusion—is likely to alter when nodes are
invaded with tumour. Only a few studies, mainly in head/neck
and uterine/cervical cancer, have focussed on DWI for lymph
node characterisation and most showed only a per patient or
per region validation [13–23]. To our knowledge there have
been no reports so far of a per node DWI validation study in
rectal cancer and in particular focussing on nodal restaging
after CRT.
This study therefore aims to assess the diagnostic value of
diffusion-weighted MRI for nodal staging in rectal cancer
patients undergoing preoperative chemoradiation therapy,
using a lesion-by-lesion histological validation as the reference
standard. A second aim is to evaluate the interobserver
reproducibility for ADC measurements of rectal cancer nodes.
Materials and methods
Patients
Between April 2008 and December 2009, 40 consecutive
locally advanced rectal cancer patients were considered for
inclusion in this prospective study. The study was part of a
nodal imaging study, approved by the local institutional
review board, for which all patients provided written
informed consent. Inclusion criteria consisted of (a)
biopsy-proven rectal adenocarcinoma, (b) locally advanced
disease, defined on primary staging T2W-MRI as tumour in
the distal rectum (≤ 5 mm from the anorectal junction),
tumour involvement of the circumferential resection mar-
gins and/or positive nodal stage, and (c) treatment consist-
ing of CRT + resection. Ten patients were excluded; 3 did
not undergo surgery, in 2 patients the MR images showed
severe metal implant artefacts and in 5 patients there was no
PhD fellow present during histopathological evaluation so
that a lesion-by-lesion matching could not be performed.
This left a total of 30 patients (25 male, 5 female; median
age 71 years, range 47–90) who were included in the study.
The CRT consisted of 28×1.8 Gy and 2×825 mg/m
2/d
capecitabine, followed by a restaging MRI 6–8 weeks after
completion of CRT and subsequent surgery.
MR imaging
Patients did not receive a bowel preparation or spasmo-
lytics. Imaging was performed with a 1.5-T MR unit
(Intera; Philips Medical Systems, Best, The Netherlands)
using a a phased-array body coil. The imaging protocol
consisted of standard 2D T2-weighted (T2W) fast spin-echo
sequences in three orthogonal directions (TR/TE 3427/
150 msec, 90° flip angle, 25 echotrain length, 6 NSA,
0.78×1.14×5.00 mm acquisition voxel size, 22 slices,
5.08 min acquisition time). For study purposes, two
additional sequences were performed; (a) an axial
diffusion-weighted sequence with background body signal
suppression (DWIBS [24], b-values 0,500,1000 s/mm
2, TR/
TE 4829/70 msec, EPI factor 53, 4 NSA, 2.50×3.11×
5.00 mm acquisition voxel size, 50 slices, 10.37 min
acquisition time) and (b) an axial 3DT1W gradient-echo
(GRE) sequence (TR/TE 9.8/4.6 msec, 15° flip angle, 1
NSA, 1.15×1.15×1.00 mm acquisition voxel size, 200
slices, 6.30 min acquisition time). The 3DT1W GRE
sequence is not part of a standard rectal MRI protocol,
but was used as a roadmap to depict small lymph nodes and
confirm them anatomically as nodes and not vessels.
Table 1 Criteria for benign and malignant nodes on T2-weighted MRI
Confidence Level Criteria
0 size ≤ 5 mm + regular border/shape + homogeneous signal pattern
1 size ≤ 5 mm + irregular border/shape or heterogeneous signal pattern
2 size > 5 or irregular border/shape or heterogeneous signal pattern
3 any size + irregular border/shape + heterogeneous signal pattern
4 size > 5 mm + irregular border/shape + heterogeneous signal pattern
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The MR images were independently analysed by two
readers: a senior (RGHBT) and junior (FCHB) gastrointes-
tinal radiologist with 13 and 3 years of respective expertise
in reading pelvic MRI. The readers were blinded to each
other’s results. The pre-treatment images were used to
identify the primary tumour and nodes. Lymph nodes were
then identified on the post-treatment 3DT1W GRE images
and drawn on an anatomical map, used as a template to
ensure exact lesion-by-lesion matching with nodes har-
vested at histology [25]. On T2W-MRI each visible lymph
node was scored using a 5-point confidence level score
(Table 1). Criteria for malignancy were > 5 mm in size +
spiculated or indistinct border and/or heterogeneous signal
pattern [26, 27].
Visual diffusion analyses
In the same reading session, the readers evaluated the
visibility of lymph nodes on the b1000 images. A lymph
node was defined as a round/oval, high signal intensity
structure corresponding with a node on the anatomical
T1W GRE (Fig. 1). The signal of each node was
subjectively scored as ‘high’, ‘average’ or ‘low’, with
the signal of the primary tumour (on pre-treatment MRI)
as the reference for ‘high’, the signal of the prostate/
uterus for ‘average’ and the signal of the normal rectal
wall for ‘low’.
ADC analyses
ADC maps in greyscale were automatically generated at the
operating system, using al three b-values. To evaluate
interobserver reproducibility, two radiological PhD
fellows (DMJL and MM) independently performed
ADC measurements of all visible nodes, blinded to
each other’s results and the radiologists’ scores. An
oval-shaped region of interest (ROI) was manually
drawn for each node on the b1000 images and copied
to the ADC map. ROI size was chosen to include as
much of the nodal parenchyma as possible. ADCs were
Fig. 1 a 3DT1W GRE images
with 1-mm isotropic voxels
were used for accurate depiction
of lymph nodes (arrowheads). b
Nodes were scored as benign or
malignant on standard T2W
FSE images. c Nodes were
identified on DWI, where
regions of interest were placed
and copied to the ADC map. d
Nodal ADC was calculated from
the ADC map including b-
values 0, 500 and 1000 s/mm
2
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nostic analyses.
Lesion-by-lesion histological evaluation
All patients underwent a total mesorectal excision. To
provide accurate matching with the axial MRI, each
specimen was sectioned perpendicular to the rectal
lumen, every 5 mm. Each section was searched for
lymph nodes by a dedicated pathologist (RGR). Optimal
nodal matching was obtained by side by side compar-
ison of the anatomical map with the axially sliced
specimen, with special attention for the nodal size and
the location of the nodes in relation to surrounding
structures [25]. The matching process was performed in
consensus by a PhD fellow (DMJL) and the pathologist.
Each node was placed in a marked individual tray and
processed according to standard methods. For each
malignant node the pathologist reported the percentage
of the node that contained normal lymphoid tissue,
metastatic changes or necrosis, respectively.
Statistical analyses
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS, version 16.0,
Inc., Chicago, IL, USA). Weighted kappa values with
quadratic weighting were calculated to determine inter-
observer agreement (IOA) for T2W-MRI. IOA for the
nodal ADC measurements was analysed according to
the method of Bland and Altman [28] and by calculating
the intraclass correlation coefficient (ICC). A Student’s T
t e s tw a su s e dt oc o m p a r eA D C( m e a no ft w oo b s e r v e r s )
between benign and malignant nodes. Receiver operator
characteristics (ROC) curve analyses were performed to
evaluate the diagnostic performance for (a) T2W-MRI,
(b) ADC, and (c) the combination of T2W-MRI + ADC.
For the latter, a predicted probability derived from a
logistic regression analysis (using ADC and the confi-
dence levels from T2W-MRI as independent variables
and histologically benign/malignant as the dependent
variable) was used as a test variable. Corresponding areas
under the ROC curve (AUC), sensitivity, specificity,
positive and negative predictive values and overall
accuracy were calculated. For T2W-MRI the confidence
levels were dichotomised with the cut-off set between 2
(possibly malignant) and 3 (probably malignant). For the
ADC and combined T2W + ADC, the cut-offs were
determined according to the point nearest to the upper
left corner in the ROC curves. Each node that was not
identified on T2W-MRI and/or DWI was assigned a
negative score. Differences in diagnostic performance
were analysed by comparing the ROC curves according
to the method described by DeLong et al. [29]. P values<
0.05 were considered statistically significant.
Results
Histopathology
At histology 19 patients had a ypN0, 7 a ypN1 and 4 a
ypN2 status. A total number of 321 nodes was harvested
(median 12 nodes per patient; range 1–24; 281 N−, 40 N+).
A node-by-node MR-histological analysis of 222 nodes
could be performed (median size 3 mm, range 2–16 mm),
of which 188 were benign and 34 were malignant. The
other 99 harvested nodes were excluded because they could
not be matched with MRI.
Interobserver agreement
IOA for the confidence level scores on T2W-MRI was good
(κ 0.73). IOA for the visual (signal intensity) evaluation on
DWI was moderate (κ 0.43). The Bland-Altman plot for the
ADC measurements is displayed in Fig. 2. The mean bias
in ADC between the two readers was 0.064 *10
−3 mm
2/s
and limits of agreement were ±0.442 *10
−3 mm
2/s. The
ICC was 0.77.
Diagnostic performance of T2W-MRI
On T2W-MRI, 101/222 (45%) nodes were identified
(median size 4 mm; range 2–16 mm; 27 N+, 74 N−). The
Fig. 2 Interobserver reproducibility for nodal ADC measurements.
Bland-Altman plot of the mean ADC of the two observers (x-axis)
against the difference in ADC between the two observers (y-axis). The
continuous line represents the mean absolute difference (bias) in ADC
between the two observers; the dashed lines represent the 95%
confidence intervals of the mean difference (limits of agreement)
268 Eur Radiol (2011) 21:265–273AUC for detection of metastatic nodes was 0.88 for reader
1 and 0.95 for reader 2. Sensitivity was 65%, specificity
93%, PPV 61% and NPV 94% for reader 1. These values
were 71%, 91%, 60% and 95% for reader 2.
Visual evaluation of DWI
On the b1000 images, 157/222 (71%) nodes were identified
(median size 3 mm; range 2–16 mm; 37 N+, 180 N−).
Signal intensities did not differ between the benign and
metastatic nodes (Fig. 3) and rendered an AUC of 0.64
(95% CI 0.53–0.75) for reader 1 and 0.52 (95% CI 0.40–
0.64) for reader 2.
Diagnostic performance of ADC
Of the 157 nodes identified on DWI, ADC measurements
could be obtained in 115 nodes. The remaining 42 nodes
were excluded because the nodes were too small to place
an ROI or the standard errors of the ADC measurements
were too large, because of local image distortions. Mean
ADC was 1.19±0.27 *10
−3 mm
2/s for the benign and
1.43±0.38 *10
−3 mm
2/s for the malignant nodes (p<
0.001). AUC for detection of metastatic nodes was 0.66.
The optimal ADC threshold was 1.25 *10
−3 mm
2/s,
resulting in a sensitivity of 53%, specificity 82%, PPV
35% and NPV 91%.
Diagnostic performance of T2W-MRI + ADC
For 69 nodes, ADCs and T2W confidence level scores
could be combined. For the other nodes, ADC was not
available and/or the nodes were not visualised on T2W-
MRI. The predicted probability for the combined assess-
ment of T2W-MRI + ADC derived from the logistic
regression rendered an AUC of 0.91 for reader 1 and 0.96
for reader 2. The optimal predicted probability was 0.51 for
reader 1 and 0.69 for reader 2, which resulted in a
sensitivity of 56%, specificity 98%, PPV 83% and NPV
92% for reader 1. These values were 56%, 99%, 95% and
93% for reader 2.
The diagnostic predictive values for the three reading
methods are displayed in Table 2. The ROC curves are
displayed in Fig. 4. The diagnostic performance when using
ADC only was significantly lower than for T2W-MRI (p=
0.02 and p=0.0003 for readers 1 and 2, respectively) and
T2W-MRI + ADC combined (p=0.001 and p<0.0001).
There was no significant difference in diagnostic perfor-
mance between T2W-MRI and the combination of T2W +
ADC (p=0.17 and p=0.26).
Histological features of the malignant nodes
In 22% of the malignant nodes, > 50% of the node
consisted of necrosis. In 17% of the nodes, 10–30% of
the node was necrotic (Fig. 5b). In the other 61% of
nodes there was no or only a little (< 5%) necrosis. Of
these nodes, a normal lymphoid architecture was pre-
served in a large proportion (> 20%) of the node in 45%
of the cases (Fig. 5a). These nodes with a relatively
preserved lymphoid architecture showed low ADC
values (1.16±0.14 *10
−3 mm
2/s) that were comparable
to the benign nodes (1.19±0.27 *10
−3 mm
2/s, p=0.49)
but were lower compared with the nodes that were fully
metastatic or necrotic (1.40±0.28 *10
−3 mm
2/s), al-
though this difference did not reach statistical signifi-
cance (p=0.08).
Discussion
The goal of this study was to evaluate the diagnostic
performance of DWI in addition to standard T2W-MRI
for the evaluation of rectal cancer lymph nodes after
neoadjuvant chemoradiation treatment. Our results indi-
cate that visual DWI evaluation improves the number of
lymph nodes detected (from 45% to 71%) but that it is
not useful for discrimination between benign and
metastatic nodes. The mean ADCs of lymph nodes are
discriminative with significantly higher values for the
malignant nodes. However, we found an overlap in
ADC between the benign and malignant nodes and
insufficient accuracy when using ADC only for the
detection of nodal metastases. ADC combined with
standard T2W-MRI improved the diagnostic perfor-
100%
80%
60%
High Average
40%
Low
20%
0%
Obs 1 Obs 2 Obs 1 Obs 2
N+ nodes N- nodes
Fig. 3 Distribution of subjectively scored signal intensities on DWI
for benign and malignant nodes. The bars represent the proportion (%)
of ‘low’, ‘average’ and ‘high’ signal intensities for the two readers
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ment compared with T2W-MRI only.
Our results thus suggest that after chemoradiation, T2W-
MRI on its own is already sufficient for nodal evaluation,
reaching an AUC of 0.88–0.95. Such good results have also
been reported by previous authors, with high NPVs ranging
between 81% and 100%, indicating that a restaging MRI
after CRT can accurately identify the ypN0 patients [10,
11]. This is remarkable, as it is known from two recent
meta-analyses that MRI generally performs poorly for
nodal staging [8, 9]. It has to be noted, however, that
these meta-analyses only included studies that focussed
on primary nodal staging. Apparently, morphological
criteria (size, shape and border) work better in a restaging
setting. Many small (2–5 mm) nodes disappear after CRT,
while up to 50% of these nodes initially contained
metastases [30, 31]. Of the small nodes that remain
visible after CRT, up to 90% are sterilised [32]. Nodes
that remain large are thus more likely to be malignant.
Overall this facilitates a more reliable assessment of
nodes based on morphological criteria only on a restaging
MRI.
We found a significant difference in ADC between
benign and malignant nodes. Nevertheless, there was a
considerable overlap in values, making it difficult to
identify a clinically reliable threshold for malignancy. With
the optimal threshold of 1.25 *10
−3 mm
2/s, a high NPV of
91% could only be obtained at the cost of a low PPV of
35%. This is in concordance with the previous results of
Kim et al. who measured nodal ADCs in 125 cervical
cancer patients and achieved a NPV of 99% on a patient
basis, but a PPV of only 38%, leading to overstaging in a
huge proportion of patients [19]. Of interest was our finding
that, although it did not improve the overall performance,
the addition of ADC to standard T2W-MRI did improve the
PPV from 60–61% to 83–95%, thus reducing the over-
staging errors.
Table 2 Diagnostic predictive values for discrimination between benign and malignant nodes
Statistic T2W Mean ADC T2W + ADC
R1 R2 R1 R2
Sensitivity 65 (22 / 34) 71 (24 / 34) 53 (18 / 34) 56 (19 / 34) 56 (19 / 34)
95% CI 51–76 57–82 38–67 44–63 46–58
Specificity 93 (174 / 188) 91 (172 / 188) 82 (154 / 188) 98 (184 / 188) 99 (187 / 188)
95% CI 90–95 89–94 79–84 96–99 98–100
PPV 61 (22 / 36) 60 (24 / 40) 35 (18 / 52) 83 (19 / 23) 95 (19 / 20)
95% CI 48–72 48–69 25–44 66–93 79–99
NPV 94 (174 / 186) 95 (172 / 182) 91 (154 / 170) 92 (184 / 199) 93 (187 / 202)
95% CI 91–96 92–97 88–93 91–94 91–93
Accuracy 88 (196 / 222) 88 (196 / 222) 77 (172 / 222) 91 (203 / 222) 93 (206 / 222)
95% CI 84–92 84–92 73–82 88–94 90–94
AUC 0.88 0.95 0.66 0.91 0.96
95% CI 0.78–0.97 0.90–1.0 0.51–0.81 0.82–1.0 0.92–1.0
Numbers are percentages. Absolute numbers are given in parentheses. 95% CI=95% Confidence Interval
Fig. 4 ROC curves used to evaluate the diagnostic performance for
the detection of metastatic nodes for (a) T2-weighted (T2W) MRI
only, (b) ADC measurements only and (c) for the combined
assessment of T2W-MRI + ADC. There was no significant difference
in performance between the use of T2W-MRI only, and the
combination of T2W-MRI + ADC (p=0.17 for reader 1 and 0.26 for
reader 2). The use of ADC measurements only resulted in significantly
worse performance than for T2W-MRI only or the combination of
T2W-MRI + ADC
270 Eur Radiol (2011) 21:265–273Contrary to most nodal DWI reports, we found signif-
icantly higher ADCs for the metastatic nodes. This
discrepancy may be attributed to the fact that we included
patients who all had undergone preoperative chemoradia-
tion. It is known that irradiated malignant nodes often
become (partly) necrotic. Due to a loss of cell structure,
these necrotic areas are associated with increased diffusiv-
ity, resulting in higher ADCs. At histology, large areas of
necrosis were present in over one third of the metastatic
nodes (Fig. 5b), which may explain the higher ADCs found
for the malignant nodes in our study. Previous studies in
head/neck and oesophageal cancer also reported higher
ADCs in metastatic nodes and found necrotic changes to be
the major reason [16, 17, 33]. Interestingly, in studies that
reported lower ADC values, none of the patients had been
irradiated [14, 15, 19–21, 23].
Interobserver agreement for ADC measurements was
good (ICC 0.77). However, the limits of agreement from
the Bland-Altman plot (±0.442 *10
−3 mm
2/s) exceeded the
mean absolute difference of 0.240 *10
−3 mm
2/s in ADC
between the benign and malignant nodes, thus limiting the
clinical utility of ADC. This was also observed in a
previous study by Kwee et al. [34]. Although ADC
measurements provide objective, quantifiable information,
the manual placement of ROIs remains a subjective action
and will limit reproducibility.
The ADC thresholds in our study were only tested
retrospectively, whereas ideally these thresholds should be
testedprospectively.Atthesametimewerealisethatmeasuring
nodal ADCs requires a considerable time investment from a
radiologist in a busy clinical practice. Furthermore, ADC
measurements are influenced by MR equipment, imaging
parameters and methods of analyses. It will therefore be
difficult to obtain uniform thresholds that can be broadly
implemented into clinics. Further research should therefore
focus on standardising imaging and analyses protocols.
The main gain from the addition of DWI was the
improved number of detected nodes compared with T2W-
MRI. On DWI, high signal intensity nodes were more
easily detected against the suppressed background signal of
the surrounding tissues. DWI can thus be used to
immediately focus a radiologist’s eye on the presence of
nodes and reduce the time needed for the evaluation of
nodal status.
Clinical impact
Accurate nodal restaging after chemoradiation may have a
substantial impact on therapeutic decision-making. While at
present all patients with locally advanced rectal cancer
undergo preoperative chemoradiation followed by a total
mesorectal excision, minimally invasive treatments could
be a safe alternative when patients with a node-negative
status and a good response of the primary tumour can be
accurately selected. Although these treatment alternatives
are still under debate, the gradual shift within the near
future will be towards organ-saving surgery for the good
responders. When we can provide a tool for better selection
of these patients, in particular for the selection of those with
truly sterilised nodes, patients with a small tumour remnant
(ypT1-2N0) may be safely stratified for a local excision,
while patients with a complete response (ypT0N0) could go
for a wait-and-see policy [6, 7].
In conclusion, this study shows that after chemoradiation
ADC measurements may have the potential for nodal
characterisation in rectal cancer, but DWI as a stand alone
technique is not reliable. The main gain from the addition
of DWI is an increase in the number of detected nodes and
an improved PPV for identification of metastatic nodes.
However, it does not improve overall diagnostic perfor-
mance and after CRT, T2W-MRI on its own is already
sufficiently accurate.
Fig. 5 Histological evaluation of 2 metastatic lymph nodes (haema-
toxylin and eosin staining; original magnification 50×). a Lymph node
with a relatively preserved lymphoid architecture, where only small
nests of metastatic adenocarcinoma can be visualised (arrowheads).
This node still resembled a healthy lymph node and showed relatively
low ADC. b Example of a node with large areas of necrosis (arrows).
Because of the decreased cellular density in these necrotic areas, this
node showed a relatively high ADC
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